Yan Zhiwu (燕之屋), the Hong Kong‑listed bird’s‑nest specialist (01497.HK), posted a rare mixed result for its fiscal 2025: revenue slipped while profit rose sharply, a pattern that exposed both the limits of China’s high‑end tonic market and the lengths the company is going to arrest a slowdown. Management has leaned on productivity upgrades, cost cutting and a strategic push to translate a historically elite ingredient into lower‑price, everyday formats — from breakfast porridges to peptide‑infused drinks — even as offline channels contract.
The company reported revenue of RMB 2.001 billion in 2025, down 2.41% year‑on‑year, and net profit attributable to shareholders of RMB 189 million, up 20.64%. Gross margin improved by 4.13 percentage points to 53.53% after sales costs fell from about RMB 1.037 billion in 2024 to RMB 930 million in 2025, reflecting the impact of a new smart factory and process upgrades.
Cost control has been the principal engine behind the profit rebound. Yan Zhiwu reduced sales and distribution expenses slightly and cut R&D by about 10.6%; financial costs also eased. Headcount fell by 234 employees to 1,635, yet reported labour costs stayed flat at roughly RMB 292 million because of director and share‑based payouts, underscoring limited short‑term payroll relief.
Channel weakness remains the immediate operational headache. Yan Zhiwu saw a net reduction in offline dealer outlets and recorded significant declines in direct sales to distributors and other offline customers. By year‑end it had 620 dealer stores, 30 fewer than a year earlier, and 112 self‑operated stores, a marginal increase; offline revenue declines prompted a goodwill impairment of about RMB 14.2 million.
Product mix shows why the company faces a growth puzzle. Pure bird’s‑nest products — bowls, bottled and dried formats — remain the core, accounting for 88.5% of sales at RMB 1.771 billion but down 1.35% year‑on‑year. The newer "bird’s‑nest+" formats that had surged in 2024, driven by porridge positioned for breakfast and snack occasions, cooled in 2025 to RMB 216 million, down 6.9%. Non‑core categories such as mooncakes and snacks contracted sharply after SKU rationalization.
In response, Yan Zhiwu is experimenting with lower‑price consumption scenarios and ingredient extensions. It has launched a branded peptide arm, YANPEP, and trialled bird’s‑nest tea and peptide‑fortified waters, probiotics and protein mixes targeting sleep, skin and vitality niches. The company is also beefing up private‑domain efforts — member events, sports and lifestyle tie‑ins and a Shanghai ‘‘global members’ house’’ — to monetise a reported 580,000‑member base.
Marketing moves have been bold but mixed. A high‑price "President Bowl" endorsed briefly by a high‑profile entrepreneur grabbed headlines but produced no disclosed sales boom; later, the brand signed actor Zhu Yilong and appointed Gong Li as co‑ambassadors in a bid to broaden appeal and refresh its premium image without losing credibility among more price‑sensitive buyers.
Why this matters: bird’s nest is emblematic of China’s broader premium consumables market, where discretionary, status‑oriented purchases are vulnerable to shifts in macro spending and demographics. Yan Zhiwu’s results suggest many incumbents can gain short‑term margin relief from operational efficiency, yet long‑term value hinges on either reinstating premium demand or successfully converting a new, larger mainstream audience to pay for formerly luxury ingredients.
Outlook is uncertain. The company’s dividend proposal looks designed to steady investor nerves, but market reaction was muted. A rebalancing strategy that simultaneously defends premium positioning while pursuing mass‑market penetration is difficult to pull off: too much down‑market extension risks brand dilution, while an exclusive tilt leaves the company exposed if high‑end demand wanes further.